牛牛AI助理已提取核心訊息
On December 21, 2023, Biodexa Pharmaceuticals PLC reported a significant filing with the United States Securities and Exchange Commission. The Schedule 13G filing indicated that Bigger Capital Fund, LP, along with related entities and Michael Bigger, collectively hold a substantial stake in the company. The filing, dated February 12, 2024, shows that Bigger Capital Fund, LP, and its general partner Bigger Capital Fund GP, LLC, as well as District 2 Capital Fund LP and its associated entities, each own 9.9% of Biodexa Pharmaceuticals, with a combination of ordinary shares and shares issuable upon the exercise of warrants. The warrants are subject to a beneficial ownership limitation, which prevents the reporting persons from exceeding a 9.99% ownership stake in the company. The filing also includes a joint filing agreement indicating that the statement is filed on behalf of each reporting person in accordance with SEC regulations.
On December 21, 2023, Biodexa Pharmaceuticals PLC reported a significant filing with the United States Securities and Exchange Commission. The Schedule 13G filing indicated that Bigger Capital Fund, LP, along with related entities and Michael Bigger, collectively hold a substantial stake in the company. The filing, dated February 12, 2024, shows that Bigger Capital Fund, LP, and its general partner Bigger Capital Fund GP, LLC, as well as District 2 Capital Fund LP and its associated entities, each own 9.9% of Biodexa Pharmaceuticals, with a combination of ordinary shares and shares issuable upon the exercise of warrants. The warrants are subject to a beneficial ownership limitation, which prevents the reporting persons from exceeding a 9.99% ownership stake in the company. The filing also includes a joint filing agreement indicating that the statement is filed on behalf of each reporting person in accordance with SEC regulations.
2023年12月21日，Biodexa Pharmicals PLC報告了向美國證券交易委員會提交的一份重要文件。附表13G的文件顯示，Bigger Capital Fund有限責任公司以及關聯實體和邁克爾·比格共同持有該公司的大量股份。這份日期爲2024年2月12日的文件顯示，Bigger Capital Fund, LP及其普通合夥人Bigger Capital Fund GP, LLC以及第二區資本基金有限責任公司及其關聯實體各擁有Biodexa Pharmicals9.9％的股份，包括普通股和行使認股權證時可發行的股份。認股權證受實益所有權限制，這防止申報人超過公司9.99％的所有權。該文件還包括一份聯合申報協議，表明該聲明是根據美國證券交易委員會的規定代表每個申報人提交的。
2023年12月21日，Biodexa Pharmicals PLC報告了向美國證券交易委員會提交的一份重要文件。附表13G的文件顯示，Bigger Capital Fund有限責任公司以及關聯實體和邁克爾·比格共同持有該公司的大量股份。這份日期爲2024年2月12日的文件顯示，Bigger Capital Fund, LP及其普通合夥人Bigger Capital Fund GP, LLC以及第二區資本基金有限責任公司及其關聯實體各擁有Biodexa Pharmicals9.9％的股份，包括普通股和行使認股權證時可發行的股份。認股權證受實益所有權限制，這防止申報人超過公司9.99％的所有權。該文件還包括一份聯合申報協議，表明該聲明是根據美國證券交易委員會的規定代表每個申報人提交的。
有用
沒用